Anthony Fauci, MD, director or the National Institute of Allergy and Infectious Disease (NIAID) and White House public health advisor, is concerned that a potential vaccine to protect against the novel coronavirus, COVID-19, may not deliver long-term immunity.

Jerome Labat has been hired as Cerner Corporation’s new chief technology officer.

As some states reopen businesses and more Americans will resume visiting their doctors, clinicians are concerned about a second wave of COVID-2 infections, according to a survey of clinical leaders.

The World Health Organization has suspended the trial of the controversial drug hydroxychloroquine due to safety concerns.

Dick Daniels, chief information officer and vice president at Kaiser Permanente, announced his decision to retire mid-June.

Technology companies Apple and Google have teamed up to build an element of contact tracing to aid in the COVID-19 response.

Biopharmaceutical company AstraZeneca has received more than $1 billion in funding from BARDA for the development, production and delivery of Oxford University's vaccine for COVID-19.

CMS has issued a plan to reopen the nation’s nursing homes with a new guidance for state and local officials.

President Trump recently stated he was taking hydroxychloroquine, an anti-malaria drug that has been unproven to prevent or treat infection of COVID-19. Trump has touted the drug over the past several weeks for benefitting COVID-19 patients, but studies have shown little to no impact.

Just six months after Haven piloted its initial health-benefits plans, Atul Gawande, MD, MPH, is relinquishing his role as the fledgling organization’s CEO.

Using such metrics as telehealth adoption and pledges of free vaccine when one becomes available, WalletHub has ranked the states in order of most to least supportive of at-risk populations during the pandemic.

The altered landscape presents U.S. healthcare providers with an unavoidable question: What will our operations look like post COVID-19?